Roivant Sciences annual shareholders’ equity
2020
2021
2022
2023
2024
2025
Roivant Sciences Shareholders’ Equity Growth & History (ROIV)
Roivant Sciences's shareholders’ equity was $4.53B for fiscal 2025.
View full Roivant Sciences company overviewRoivant Sciences annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2026-03-31 | $4.53B | −$160.2M | −3.42% |
| 2024 | 2025-03-31 | $4.69B | −$1.28B | −21.46% |
| 2023 | 2024-03-31 | $5.97B | $4.81B | +415.53% |
| 2022 | 2023-03-31 | $1.16B | −$499.2M | −30.13% |
| 2021 | 2022-03-31 | $1.66B | −$140.8M | −7.83% |
| 2020 | 2021-03-31 | $1.80B | — | — |
Roivant Sciences quarterly shareholders’ equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-06-30 | $4.23B | −$114.4M | −2.63% |
| Q4 2025 | 2026-03-31 | $4.53B | −$160.2M | −3.42% |
| Q3 2025 | 2025-12-31 | $4.27B | −$920.2M | −17.73% |
| Q2 2025 | 2025-09-30 | $4.36B | −$790.6M | −15.34% |
| Q1 2025 | 2025-06-30 | $4.35B | −$1.09B | −20.05% |
| Q4 2024 | 2025-03-31 | $4.69B | −$1.28B | −21.46% |
| Q3 2024 | 2024-12-31 | $5.19B | −$900.3M | −14.78% |
| Q2 2024 | 2024-09-30 | $5.15B | $4.20B | +443.25% |
| Q1 2024 | 2024-06-30 | $5.44B | $4.52B | +496.81% |
| Q4 2023 | 2024-03-31 | $5.97B | $4.81B | +415.53% |
| Q3 2023 | 2023-12-31 | $6.09B | $5.13B | +537.32% |
| Q2 2023 | 2023-09-30 | $948.5M | −$212.1M | −18.27% |
| Q1 2023 | 2023-06-30 | $910.7M | −$473.4M | −34.20% |
| Q4 2022 | 2023-03-31 | $1.16B | −$499.2M | −30.13% |
| Q3 2022 | 2022-12-31 | $955.5M | −$910.2M | −48.79% |
| Q2 2022 | 2022-09-30 | $1.16B | −$877.4M | −43.05% |
| Q1 2022 | 2022-06-30 | $1.38B | −$339.0M | −19.67% |
| Q4 2021 | 2022-03-31 | $1.66B | −$140.8M | −7.83% |
| Q3 2021 | 2021-12-31 | $1.87B | — | — |
| Q2 2021 | 2021-09-30 | $2.04B | — | — |
| Q1 2021 | 2021-06-30 | $1.72B | — | — |
| Q4 2020 | 2021-03-31 | $1.80B | — | — |
Roivant Sciences shareholders’ equity trends
Over the last five fiscal years, Roivant Sciences's shareholders’ equity increased from $1.80B to $4.53B, a change of $2.73B. The latest reported quarter, Q1 2026, shows $4.23B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Roivant Sciences source filings ↗